ログイン
言語:

WEKO3

  • トップ
  • ランキング
To
lat lon distance
To

Field does not validate



インデックスリンク

インデックスツリー

メールアドレスを入力してください。

WEKO

One fine body…

WEKO

One fine body…

アイテム

{"_buckets": {"deposit": "f1468602-87d5-416e-bfbc-5e13fdeda047"}, "_deposit": {"id": "2002120", "owners": [1], "pid": {"revision_id": 0, "type": "depid", "value": "2002120"}, "status": "published"}, "_oai": {"id": "oai:nagoya.repo.nii.ac.jp:02002120", "sets": ["1646019880489"]}, "author_link": [], "control_number": "2002120", "item_1615768549627": {"attribute_name": "出版タイプ", "attribute_value_mlt": [{"subitem_version_resource": "http://purl.org/coar/version/c_970fb48d4fbd8a85", "subitem_version_type": "VoR"}]}, "item_9_biblio_info_6": {"attribute_name": "書誌情報", "attribute_value_mlt": [{"bibliographicIssueDates": {"bibliographicIssueDate": "2022-02", "bibliographicIssueDateType": "Issued"}, "bibliographicIssueNumber": "1", "bibliographicPageEnd": "90", "bibliographicPageStart": "80", "bibliographicVolumeNumber": "84", "bibliographic_titles": [{"bibliographic_title": "Nagoya Journal of Medical Science", "bibliographic_titleLang": "en"}]}]}, "item_9_description_4": {"attribute_name": "内容記述", "attribute_value_mlt": [{"subitem_description": "More than 40% of Japanese patients with multiple myeloma (MM) are over 75 years of age at diagnosis. Regardless of the treatment benefits, complications and relapses obstruct long-term survival. We conducted a phase II, open-label, single-arm, multicenter clinical trial to assess the efficacy and safety of alternating bortezomib-dexamethasone (Bd) and lenalidomide-dexamethasone (Ld) (Bd/Ld) treatment in MM patients aged over 75 years (MARBLE trial). Patients received Bd therapy from days 1 to 35 and Ld therapy from days 36 to 63. For Bd therapy, patients were administered bortezomib 1.3 mg/m2 and oral dexamethasone 20 mg on days 1, 8, 15, and 22. For Ld therapy, they were administered lenalidomide 15 mg from days 36 to 56 and dexamethasone 10 mg on days 36, 43, 50, and 57. They underwent six treatment cycles in total, each consisting of a 63-day regimen. In total, 10 patients were enrolled, with a median age of 81 years. Efficacy was not evaluated because the patients were fewer than planned. The overall response rate was 80.0% and complete response rate 40.0%. Seventy percent of patients completed the study treatment. Progression-free survival and overall survival at 2 years were 40.0% and 80.0%, respectively. Adverse events of grade 3 or higher, including anemia, decreased lymphocyte count, neutropenia, and hypokalemia, were observed in eight patients. Alternating chemotherapy with Bd/Ld might be feasible, but its efficacy should be verified further.", "subitem_description_language": "en", "subitem_description_type": "Abstract"}, {"subitem_description": "This is an Open Access article distributed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License. To view the details of this license, please visit (http://creativecommons.org/licenses/by-nc-nd/4.0/).", "subitem_description_language": "en", "subitem_description_type": "Other"}]}, "item_9_identifier_registration": {"attribute_name": "ID登録", "attribute_value_mlt": [{"subitem_identifier_reg_text": "10.18999/nagjms.84.1.80", "subitem_identifier_reg_type": "JaLC"}]}, "item_9_publisher_32": {"attribute_name": "出版者", "attribute_value_mlt": [{"subitem_publisher": "Nagoya University Graduate School of Medicine, School of Medicine", "subitem_publisher_language": "en"}]}, "item_9_relation_43": {"attribute_name": "関連情報", "attribute_value_mlt": [{"subitem_relation_type": "isVersionOf", "subitem_relation_type_id": {"subitem_relation_type_id_text": "https://www.med.nagoya-u.ac.jp/medlib/nagoya_j_med_sci/841.html", "subitem_relation_type_select": "URI"}}]}, "item_9_source_id_7": {"attribute_name": "収録物識別子", "attribute_value_mlt": [{"subitem_source_identifier": "0027-7622", "subitem_source_identifier_type": "PISSN"}, {"subitem_source_identifier": "2186-3326", "subitem_source_identifier_type": "EISSN"}]}, "item_access_right": {"attribute_name": "アクセス権", "attribute_value_mlt": [{"subitem_access_right": "open access", "subitem_access_right_uri": "http://purl.org/coar/access_right/c_abf2"}]}, "item_creator": {"attribute_name": "著者", "attribute_type": "creator", "attribute_value_mlt": [{"creatorNames": [{"creatorName": "Yokoyama, Akihiro", "creatorNameLang": "en"}]}, {"creatorNames": [{"creatorName": "Kada, Akiko", "creatorNameLang": "en"}]}, {"creatorNames": [{"creatorName": "Kagoo, Toshiya", "creatorNameLang": "en"}]}, {"creatorNames": [{"creatorName": "Hidaka, Michihiro", "creatorNameLang": "en"}]}, {"creatorNames": [{"creatorName": "Iida, Hiroatsu", "creatorNameLang": "en"}]}, {"creatorNames": [{"creatorName": "Miyata, Yasuhiko", "creatorNameLang": "en"}]}, {"creatorNames": [{"creatorName": "Saito, Akiko M.", "creatorNameLang": "en"}]}, {"creatorNames": [{"creatorName": "Sawamura, Morio", "creatorNameLang": "en"}]}, {"creatorNames": [{"creatorName": "Komeno, Takuya", "creatorNameLang": "en"}]}, {"creatorNames": [{"creatorName": "Sunami, Kazutaka", "creatorNameLang": "en"}]}, {"creatorNames": [{"creatorName": "Takezako, Naoki", "creatorNameLang": "en"}]}, {"creatorNames": [{"creatorName": "Nagai, Hirokazu", "creatorNameLang": "en"}]}]}, "item_files": {"attribute_name": "ファイル情報", "attribute_type": "file", "attribute_value_mlt": [{"accessrole": "open_access", "date": [{"dateType": "Available", "dateValue": "2022-02-28"}], "displaytype": "detail", "download_preview_message": "", "file_order": 0, "filename": "08_Yokoyama.pdf", "filesize": [{"value": "683 KB"}], "format": "application/pdf", "future_date_message": "", "is_thumbnail": false, "mimetype": "application/pdf", "size": 683000.0, "url": {"objectType": "fulltext", "url": "https://nagoya.repo.nii.ac.jp/record/2002120/files/08_Yokoyama.pdf"}, "version_id": "e16c28a2-99b8-4e39-81f1-c2072613f3ac"}]}, "item_keyword": {"attribute_name": "キーワード", "attribute_value_mlt": [{"subitem_subject": "myeloma", "subitem_subject_language": "en", "subitem_subject_scheme": "Other"}, {"subitem_subject": "alternating therapy", "subitem_subject_language": "en", "subitem_subject_scheme": "Other"}, {"subitem_subject": "bortezomib", "subitem_subject_language": "en", "subitem_subject_scheme": "Other"}, {"subitem_subject": "lenalidomide", "subitem_subject_language": "en", "subitem_subject_scheme": "Other"}, {"subitem_subject": "dexamethasone", "subitem_subject_language": "en", "subitem_subject_scheme": "Other"}]}, "item_language": {"attribute_name": "言語", "attribute_value_mlt": [{"subitem_language": "eng"}]}, "item_resource_type": {"attribute_name": "資源タイプ", "attribute_value_mlt": [{"resourcetype": "departmental bulletin paper", "resourceuri": "http://purl.org/coar/resource_type/c_6501"}]}, "item_title": "Alternating bortezomib-dexamethasone and lenalidomide-dexamethasone in patients with newly diagnosed multiple myeloma aged over 75 years", "item_titles": {"attribute_name": "タイトル", "attribute_value_mlt": [{"subitem_title": "Alternating bortezomib-dexamethasone and lenalidomide-dexamethasone in patients with newly diagnosed multiple myeloma aged over 75 years", "subitem_title_language": "en"}]}, "item_type_id": "40001", "owner": "1", "path": ["1646019880489"], "permalink_uri": "https://doi.org/10.18999/nagjms.84.1.80", "pubdate": {"attribute_name": "PubDate", "attribute_value": "2022-02-28"}, "publish_date": "2022-02-28", "publish_status": "0", "recid": "2002120", "relation": {}, "relation_version_is_last": true, "title": ["Alternating bortezomib-dexamethasone and lenalidomide-dexamethasone in patients with newly diagnosed multiple myeloma aged over 75 years"], "weko_shared_id": -1}
  1. C100 医学部/医学系研究科
  2. C100b 紀要
  3. Nagoya journal of medical science
  4. 84(1)

Alternating bortezomib-dexamethasone and lenalidomide-dexamethasone in patients with newly diagnosed multiple myeloma aged over 75 years

https://doi.org/10.18999/nagjms.84.1.80
https://doi.org/10.18999/nagjms.84.1.80
ea5a1c8b-669c-4b00-a712-13449f29bf59
名前 / ファイル ライセンス アクション
08_Yokoyama.pdf 08_Yokoyama.pdf (683 KB)
Item type itemtype_ver1(1)
公開日 2022-02-28
タイトル
タイトル Alternating bortezomib-dexamethasone and lenalidomide-dexamethasone in patients with newly diagnosed multiple myeloma aged over 75 years
言語 en
著者 Yokoyama, Akihiro

× Yokoyama, Akihiro

en Yokoyama, Akihiro

Search repository
Kada, Akiko

× Kada, Akiko

en Kada, Akiko

Search repository
Kagoo, Toshiya

× Kagoo, Toshiya

en Kagoo, Toshiya

Search repository
Hidaka, Michihiro

× Hidaka, Michihiro

en Hidaka, Michihiro

Search repository
Iida, Hiroatsu

× Iida, Hiroatsu

en Iida, Hiroatsu

Search repository
Miyata, Yasuhiko

× Miyata, Yasuhiko

en Miyata, Yasuhiko

Search repository
Saito, Akiko M.

× Saito, Akiko M.

en Saito, Akiko M.

Search repository
Sawamura, Morio

× Sawamura, Morio

en Sawamura, Morio

Search repository
Komeno, Takuya

× Komeno, Takuya

en Komeno, Takuya

Search repository
Sunami, Kazutaka

× Sunami, Kazutaka

en Sunami, Kazutaka

Search repository
Takezako, Naoki

× Takezako, Naoki

en Takezako, Naoki

Search repository
Nagai, Hirokazu

× Nagai, Hirokazu

en Nagai, Hirokazu

Search repository
アクセス権
アクセス権 open access
アクセス権URI http://purl.org/coar/access_right/c_abf2
キーワード
言語 en
主題Scheme Other
主題 myeloma
キーワード
言語 en
主題Scheme Other
主題 alternating therapy
キーワード
言語 en
主題Scheme Other
主題 bortezomib
キーワード
言語 en
主題Scheme Other
主題 lenalidomide
キーワード
言語 en
主題Scheme Other
主題 dexamethasone
内容記述
内容記述 More than 40% of Japanese patients with multiple myeloma (MM) are over 75 years of age at diagnosis. Regardless of the treatment benefits, complications and relapses obstruct long-term survival. We conducted a phase II, open-label, single-arm, multicenter clinical trial to assess the efficacy and safety of alternating bortezomib-dexamethasone (Bd) and lenalidomide-dexamethasone (Ld) (Bd/Ld) treatment in MM patients aged over 75 years (MARBLE trial). Patients received Bd therapy from days 1 to 35 and Ld therapy from days 36 to 63. For Bd therapy, patients were administered bortezomib 1.3 mg/m2 and oral dexamethasone 20 mg on days 1, 8, 15, and 22. For Ld therapy, they were administered lenalidomide 15 mg from days 36 to 56 and dexamethasone 10 mg on days 36, 43, 50, and 57. They underwent six treatment cycles in total, each consisting of a 63-day regimen. In total, 10 patients were enrolled, with a median age of 81 years. Efficacy was not evaluated because the patients were fewer than planned. The overall response rate was 80.0% and complete response rate 40.0%. Seventy percent of patients completed the study treatment. Progression-free survival and overall survival at 2 years were 40.0% and 80.0%, respectively. Adverse events of grade 3 or higher, including anemia, decreased lymphocyte count, neutropenia, and hypokalemia, were observed in eight patients. Alternating chemotherapy with Bd/Ld might be feasible, but its efficacy should be verified further.
言語 en
内容記述タイプ Abstract
内容記述
内容記述 This is an Open Access article distributed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License. To view the details of this license, please visit (http://creativecommons.org/licenses/by-nc-nd/4.0/).
言語 en
内容記述タイプ Other
出版者
言語 en
出版者 Nagoya University Graduate School of Medicine, School of Medicine
言語
言語 eng
資源タイプ
資源タイプresource http://purl.org/coar/resource_type/c_6501
タイプ departmental bulletin paper
出版タイプ
出版タイプ VoR
出版タイプResource http://purl.org/coar/version/c_970fb48d4fbd8a85
ID登録
ID登録 10.18999/nagjms.84.1.80
ID登録タイプ JaLC
関連情報
関連タイプ isVersionOf
識別子タイプ URI
関連識別子 https://www.med.nagoya-u.ac.jp/medlib/nagoya_j_med_sci/841.html
収録物識別子
収録物識別子タイプ PISSN
収録物識別子 0027-7622
収録物識別子
収録物識別子タイプ EISSN
収録物識別子 2186-3326
書誌情報 en : Nagoya Journal of Medical Science

巻 84, 号 1, p. 80-90, 発行日 2022-02
戻る
0
views
See details
Views

Versions

Ver.1 2022-02-28 04:30:21.866908
Show All versions

Share

Mendeley Twitter Facebook Print Addthis

Cite as

エクスポート

OAI-PMH
  • OAI-PMH JPCOAR
  • OAI-PMH DublinCore
  • OAI-PMH DDI
Other Formats
  • JSON
  • BIBTEX

Confirm


Powered by WEKO3


Powered by WEKO3